Tél.: +33-(0)1 49 81 37 75
cmYubXJlc25pQG5pYW1hai5lbmFocGV0cw==
Plan d’accès vers la faculté de santé de Créteil
Plan d’accès vers l’hôpital Albert Chenevier
08/09/2025
Félicitations à Charles LAÏDI, psychiatre et enseignant-chercheur au sein de l’IMRB dans l’équipe JAMAIN/LEBOYER pour l’obtention d’une ERC Starting Grant
08/07/2024
Porté par l’UPEC au travers de la Faculté de Santé, le projet ENSUIITE coordonné par Yann SENOVA, PHU de neurochirurgie, équipe de Marion Leboyer, lauréat de l’appel à manifestation d’intérêt «Compétences et Métiers d’Avenir, volet Santé numérique»
26/05/2025
Publication d’un numéro spécial de Médecine/Sciences sur le PEPR PROPSY auquel de nombreux membres de l’équipe ont contribué
En savoir plus
Our team has been created by Prof. Marion Leboyer in 2007 to identify genetic risk factors of severe psychiatric disorders. During the last 15 years, we extended our research of risk factors by exploring environment and studying gene-environment interactions. We changed our vision of psychiatric disorders and studied clinical dimensions overlapping the classical psychiatric entities, leading to the creation of the “Translational NeuroPsychiatry” team in 2020.
Over the years, immune factors, brain imaging and genetic data revealed the necessity to define new signature-based nosography of homogenous subgroups of major psychiatric disorders paving the way towards precision medicine in psychiatry.
Today, our team is headed by Stéphane Jamain and Marion Leboyer and is composed of five research groups with extensive expertise on Functional Genomics (Stéphane Jamain), Epidemiology (Franck Schürhoff and Andrei Szoke), Brain Imaging (Pauline Favre and Charles Laïdi), Immunopsychiatry (Marion Leboyer), and Biotherapies (Stéphane Palfi).
We have built very large cohorts, which have been deeply-phenotyped using clinical, genomic, environmental, immunological and brain imaging assessments. In parallel, we have developed cellular and animal models to further decipher pathophysiological processes.
We are located on two scientific campus: the wet lab and biological experiments are conducted at Créteil (Institut Mondor de Recherche Biomédicale, UPEC-Inserm, Créteil), where patient assessment and epidemiological studies are performed through the University affiliated departments of psychiatry (Head: Prof. A. Pelissolo) and neurosurgery (Head: Prof. S. Palfi) at Mondor University Hospitals (University Paris Est Créteil and APHP, Créteil). Brain imaging exploration and preclinical models are carried out at the CEA Saclay Campus (Neurospin and NeuroPsi).
Bachellier L, Lajnef M, Lemonsu A, Fifre G, Hemery F, Rabu C, Richard JR, Leboyer M, Szöke A, Schürhoff F, Pignon B. Effect of ambient temperature and thermal comfort indices on emergency visits for psychotic and mood disorders: a case-crossover study in a French suburban area.
Psychiatry Res. 2025 Dec;354:116802.Lokmer A, Troudet R, Bacq-Daian D, Boland-Auge A, Barau C; OPTiMiSE study group; Deleuze JF, Leboyer M, Jamain S. Using blood methylomes to predict response to amisulpride in the first-episode psychosis in the OPTiMiSE cohort.
Transl Psychiatry. 2025 Oct 6;15(1):369.Saitoh K, Lajnef M, Boukouaci W, Andre M, Andrieu C, Aouizerate B, Barau C, Bouassida J, Capdevielle D, Chereau I, Clauss-Kobayashi J, Coulon N, Dorey JM, Dubertret C, Fakra E, Fond G, Goze T, Le Corvoisier P, Leignier S, Llorca PM, Mallet J, Misdrahi D, Oriol N, Pignon B, Rey R, Roux P, Schürhoff F, Schorr B, Urbach M, Very E, Wu CL; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) collaborators; Leboyer M, Godin O, Tamouza R. Pro-inflammatory processes and metabolic syndrome: combined risk of resistance to treatment in patients with schizophrenia from the FACE-SZ cohort.
Psychiatry Res. 2025 May 20;350:116557.Etain B, Lajnef M, Godin O, Marie-Claire C, Bellivier F, Courtois E, Latapie V, Gard S, Belzeaux R, Courtet P, Dubertret C, Haffen E, Lefrere A, Olie E, Polosan M, Roux P, Samalin L, Schwan R, Leboyer M, Jamain S; FondaMental Advanced Centers of Expertise in Bipolar Disorders (FACE-BD) Collaborators. Polygenic risk scores for severe psychiatric disorders in bipolar disorders: associations with the clinical and dimensional expression, interactions with childhood maltreatment and mediation models.
Transl Psychiatry. 2025 Jul 25;15(1):256.Elandaloussi Y, Dufrenne O, Lefebvre A, Houenou J, Senova S, Laidi C. Cerebellar Neuromodulation in Autism Spectrum Disorders and Social Cognition: Insights from Animal and Human Studies.
Cerebellum. 2025 Feb 12;24(2):46.El Yacoubi M, Altersitz C, Latapie V, Rizkallah E, Arthaud S, Bougarel L, Pereira M, Wierinckx A, El-Hage W, Belzeaux R, Turecki G, Svenningsson P, Martin B, Lachuer J, Vaugeois JM, Jamain S. Two polygenic mouse models of major depressive disorders identify TMEM161B as a potential biomarker of disease in humans.
Neuropsychopharmacology. 2024 Jun;49(7):1129-1139.Boukouaci W, Lajnef M, Wu CL, Bouassida J, Saitoh K, Sugunasabesan S, Richard JR, Apavou M, Lamy A, Henensal A, Nkam I, Hasty L, Sayous R, Bengoufa D, Barau C, Le Corvoisier P, Honnorat J, Maskos U, Yolken R, Leboyer M, Tamouza R. B Cell-activating factor (BAFF): A promising trans-nosographic biomarker of inflammation and autoimmunity in bipolar disorder and schizophrenia.
Brain Behav Immun. 2024 Oct;121:178-188.Krystal S, Gracia L, Piguet C, Henry C, Alonso M, Polosan M, Savatovsky J, Houenou J, Favre P. Functional connectivity of the amygdala subnuclei in various mood states of bipolar disorder.
Mol Psychiatry. 2024 Nov;29(11):3344-3355.Godin O, Pignon B, Szoke A, Boyer L, Aouizerate B, Schorr B, André M, Capdevielle D, Chereau I, Coulon N, Dassing R, Dubertret C, Etain B, Leignier S, Llorca PM, Mallet J, Misdrahi D, Passerieux C, Rey R, Urbach M, Schürhoff F, Leboyer M, Fond G. 3-year incidence and predictors of metabolic syndrome in schizophrenia in the national FACE-SZ cohort.
Prog Neuropsychopharmacol Biol Psychiatry. 2023 Jan 10;120:110641.Leboyer M, Godin O, Terro E, Boukouaci W, Lu CL, Andre M, Aouizerate B, Berna F, Barau C, Capdevielle D, Clauss-Kobayashi J, Chereau I, D Amato T, Dubertret C, Dubreucq J, Fond G, Laouamri H, Leignier S, Lancon C, Llorca PM, Mallet J, Le Corvoisier P, Misdrahi D, Passerieux C, Rey R, Pignon B, Urbach M, Szoke A, Schürhoff F, Tamouza R; FACE-SZ (FondaMental Academic Centers of Expertise for Schizophrenia) Groups. Immune Signatures of Treatment-Resistant Schizophrenia: A FondaMental Academic Centers of Expertise for Schizophrenia (FACE-SZ) Study.
Bull Open. 2021 Apr 27;2(1):sgab012.
COMPOSITION
Adresse
IMRB – Inserm U955
NeuroPsychiatrie Translationnelle (Equipe Leboyer)
Faculté de Santé de Créteil – 3ème étage
8, rue du Général Sarrail
94010 Créteil Cedex
ou
Hôpital Henri Chenevier
Pôle de Psychiatrie
40, rue de Mesly
94000 Créteil
Contact
